Research Calls I
-
Upgrades
- Chord Energy (CHRD) upgraded to Buy from Neutral at BofA Securities, tgt $114
- Crane (CR) upgraded to Buy from Neutral at UBS, tgt $190
- Diamondback Energy (FANG) upgraded to Buy from Neutral at BofA Securities; tgt $170
- Upstart (UPST) upgraded to Neutral from Underperform at BofA Securities, tgt $53
- Chord Energy (CHRD) upgraded to Buy from Neutral at BofA Securities, tgt $114
-
Downgrades
- Air Liquide (AIQUY) downgraded to Neutral from Overweight at JPMorgan
- Avantor (AVTR) downgraded to Neutral from Buy at Goldman, tgt $14
- Builders FirstSource (BLDR) downgraded to Hold from Buy at Stifel, tgt $125
- ConocoPhillips (COP) downgraded to Neutral from Buy at BofA Securities; tgt $107
- Hims & Hers (HIMS) downgraded to Hold from Buy at TD Cowen, tgt $30
- Icon (ICLR) downgraded to Neutral from Overweight at JPMorgan, tgt $150
- InMode (INMD) downgraded to Neutral from Buy at BTIG Research
- Insulet (PODD) downgraded to Peer Perform from Outperform at Wolfe Research
- Lufax (LU) downgraded to Sell from Hold at Deutsche Bank, tgt $2.40
- LVMH (LVMUY) downgraded to Neutral from Outperform at BNP Paribas Exane
- National Grid (NGG) downgraded to Neutral from Buy at UBS
- Volaris (VLRS) downgraded to Equal Weight from Overweight at Morgan Stanley, tgt $4.40
- Volaris (VLRS) downgraded to Equal Weight from Overweight at Barclays, tgt $4.50
- Air Liquide (AIQUY) downgraded to Neutral from Overweight at JPMorgan
-
Others
- Apellis (APLS) initiated with an Overweight at Cantor Fitzgerald, tgt $44
- Astria Therapeutics (ATXS) initiated with an Overweight at Cantor Fitzgerald, tgt $47
- BioCryst (BCRX) initiated with an Overweight at Cantor Fitzgerald, tgt $20
- InflaRx (IFRX) initiated with an Overweight at Cantor Fitzgerald, tgt $10
- Kinetik Holdings (KNTK) initiated with a Neutral at UBS, tgt $49
- Korro Bio (KRRO) initiated with an Overweight at Cantor Fitzgerald, tgt $74
- Matson (MATX) initiated with a Buy at Jefferies, tgt $125
- Pharvaris (PHVS) initiated with an Overweight at Cantor Fitzgerald, tgt $28
- ProQR Therapeutics (PRQR) assumed with an Overweight at Cantor Fitzgerald, tgt $8
- ProQR Therapeutics (PRQR) initiated with an Outperform at Evercore ISI, tgt $5
- Qualcomm (QCOM) resumed with an Overweight at JP Morgan; tgt lowered to $185
- Strategy (MSTR) initiated with a Buy at H.C. Wainwright, tgt $480
- Viking Therapeutics (VKTX) initiated with an Overweight at Cantor Fitzgerald, tgt $104
- Wave Life Sciences (WVE) initiated with an Overweight at Cantor Fitzgerald, tgt $10
- Apellis (APLS) initiated with an Overweight at Cantor Fitzgerald, tgt $44